Table 3 Synergistic potential of solamargine and the aqueous alkaloid-enriched fraction as described by their FIX values in a panel of cancerous and non-cancerous cell lines
Cell type | Cancerous | Non-cancerous | ||||||
|---|---|---|---|---|---|---|---|---|
Cell line | SH-SY5Y | SK-Br3 | C2C12 | EA.hy926 | ||||
Compound/Fraction | Solamargine | Aqueous alkaloid-enriched fraction | Solamargine | Aqueous alkaloid-enriched fraction | Solamargine | Aqueous alkaloid-enriched fraction | Solamargine | Aqueous alkaloid-enriched fraction |
IC50 of (A) [IC50 sample + doxorubicin (μM or μg/mL)] | 3.4 | 7.39 | 4.3 | 11.18 | 30.77 | 15.7 | 5.5 | 2.62 |
IC50 of (B) [IC50 doxorubicin + sample (nM)] | 16.27 | 24.22 | 40.83 | 47.48 | 149.9 | 140.7 | 213.4 | 220 |
IC50 (A) [Solamargine (μM) or aqueous alone (μg/mL)] | 15.62 | 26.5 | 18.59 | 19.7 | 20.25 | 13.7 | 8.3 | 7.3 |
IC50 (B) [doxorubicin alone (nM)] | 56.6 | 56.6 | 94.1 | 94.1 | 148.5 | 148.5 | 381.6 | 381.6 |
FIC (A) | 0.22 | 0.28 | 0.23 | 0.57 | 1.52 | 1.15 | 0.66 | 0.36 |
FIC (B) | 0.29 | 0.43 | 0.43 | 0.5 | 1.01 | 0.95 | 0.56 | 0.58 |
FIX value | 0.51 | 0.71 | 0.66 | 1.07 | 2.53 | 2.1 | 1.22 | 0.94 |
Result | Additive effect | Additive effect | Additive effect | Indifferent effect | Antagonistic effect | Antagonistic effect | Indifferent effect | Additive effect |